Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

NCT01632150 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

BIOLOGICAL: Elotuzumab
BIOLOGICAL: Thalidomide
BIOLOGICAL: Dexamethasone
BIOLOGICAL: Cyclophosphamide

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]